Stockscreener 앱 받기
4.26
11.80%
-0.57
전일 마감가:
$4.83
열려 있는:
$4.8
하루 거래량:
244.46K
Relative Volume:
2.13
시가총액:
$156.39M
수익:
$5.20M
순이익/손실:
$-282.61M
주가수익비율:
-0.5487
EPS:
-7.764
순현금흐름:
$-24.47M
1주 성능:
-27.67%
1개월 성능:
-43.65%
6개월 성능:
-39.57%
1년 성능:
+87.67%
1일 변동 폭
$4.16
$4.9195
1주일 범위
$4.16
$6.2185
52주 변동 폭
$2.14
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
명칭
Armata Pharmaceuticals Inc
전화
310-655-2928
주소
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
4.26 | 156.39M | 5.20M | -282.61M | -24.47M | -7.764 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-19 | 개시 | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2500 Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2000 Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Completeness Index - marketscreener.com
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – DUS:TG1N - TradingView
Price to earnings forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Price to earnings forward of Armata Pharmaceuticals, Inc. – DUS:TG1N - TradingView
Price to book forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Enterprise value to EBIT forward of Armata Pharmaceuticals, Inc. – DUS:TG1N - TradingView
Price to sales forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Price to book forward of Armata Pharmaceuticals, Inc. – BOATS:ARMP - TradingView
Enterprise value to revenue forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – BOATS:ARMP - TradingView
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
ARMP Forecast — Price Target — Prediction for 2027 - TradingView
Armata Pharmaceuticals, Inc. Actuals & Estimates (DUS:TG1N) - TradingView
Armata Pharmaceuticals, Inc. Actuals & Estimates (MUN:TG1N) - TradingView
TG1N Forecast — Price Target — Prediction for 2027 - TradingView
Armata Pharmaceuticals, Inc. Appoints Daniel Gilmer to Serve on the Nominating and Corporate Governance Committee of the Board, Effective as of June 24, 2026 - marketscreener.com
Armata Pharmaceuticals Inc. (ARMP) Climbs 4.85%, Testing Resistance at $7.72Trend Reversal Picks - dars.gov.et
Armata Pharmaceuticals (ARMP) assigns Gilmer to governance committee with $5,000 retainer - Stock Titan
Armata Pharmaceuticals (ARMP) Secures $2.5M for Clinical Development - GuruFocus
Armata Pharmaceuticals stock jumps on added DoD funding - Investing.com
Form 8K Armata Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Australia
Armata receives $2.5m DoD funding for AP-SA02 development - Investing.com UK
Armata receives $2.5m DoD funding for AP-SA02 development By Investing.com - Investing.com India
Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant - Moomoo
Armata Pharmaceuticals stock jumps on added DoD funding By Investing.com - Investing.com South Africa
Armata Pharmaceuticals Receives Additional $2.5 Million in Funding From US Department of Defense - Moomoo
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 - The AI Journal
Armata Pharmaceuticals Shares Rise on Additional $2.5 Million Government Grant - marketscreener.com
Armata gains new DoD funding for AP-SA02 advancement - TipRanks
Armata Pharmaceuticals Secures Additional $2.5M DoD Funding to Advance Phase 3 Phage Therapy for MRSA Infections 1 - Minichart
Armata Pharmaceuticals Inc (ARMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Armata Pharmaceuticals Granted FDA Fast Track Designation for AP-SA02 - HarianBasis.co
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy? - Insider Monkey
Armata Pharmaceuticals Inc (ARMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Armata Pharmaceuticals Inc (ARMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Armata Pharmaceuticals Inc - TradingKey
Armata Pharmaceuticals Inc (ARMP) Institutional Confidence - TradingKey
Armata Pharmaceuticals Inc (ARMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Armata Pharmaceuticals Inc (ARMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Armata Pharmaceuticals Inc (ARMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Armata Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Massive EPS Miss as Pre-Revenue Biotech Faces Cost Pressures - dars.gov.et
Armata Pharmaceuticals shareholders elect board and approve executive pay at annual meeting - Investing.com Canada
Armata Pharmaceuticals Inc (ARMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):